SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Klein, B. Articles by Bataille, R. Search for Related Content PubMed PubMed Citation Articles by Klein, B. Articles by Bataille, R. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6 B Klein, XG Zhang, M Jourdan, J Content, F Houssiau, L Aarden, M Piechaczyk and R Bataille INSERM U291, Zolad, Montpellier, France. To explore the mechanisms involved in the pathogenesis of human multiple myeloma (MM), we investigated the potential role of interleukin-6 (IL-6), a B-cell differentiation factor in humans, and a growth factor for rat/mouse heterohybridomas and murine plasmacytomas. Using a heterohybridoma assay, we found that two well-documented human myeloma cell lines, RPMI 8226 and U266, did not secrete IL-6 and did not express RNA messengers for IL-6. Neutralizing antibodies to IL-6 did not inhibit their proliferation, and recombinant IL-6 did not stimulate it. Taken together, these data show that IL-6 is not the autocrine growth factor of these human myeloma cell lines. A high production of IL-6 was found in the bone marrows of patients with fulminating MM, compared with patients with inactive or slightly active MM, or to healthy donors. This IL-6 production was assigned to adherent cells of the bone-marrow environment but not to myeloma cells. A spontaneous proliferation of myeloma cells freshly isolated from patients was observed in short-term cultures. Recombinant IL-6 was able to amplify it two- to threefold. The spontaneous proliferation of the myeloma cells was inhibited by anti-IL-6 antibodies and reinduced by recombinant IL-6. After 2 to 3 weeks of culture, the myeloma-cell proliferation progressively declined and no IL-6-dependent myeloma cell lines could be obtained despite repeated additions of fresh IL-6 and costimulation with other cytokines such as tumor necrosis factor (TNF)beta, or IL-1 beta. These data demonstrated a paracrine but not autocrine regulation of the growth and differentiation of myeloma cells by IL-6. Volume 73, Issue 2, pp. 517-526, 02/01/1989 Copyright © 1989 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Fulciniti, T. Hideshima, C. Vermot-Desroches, S. Pozzi, P. Nanjappa, Z. Shen, N. Patel, E. S. Smith, W. Wang, R. Prabhala, et al. A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma Clin. Cancer Res., December 1, 2009; 15(23): 7144 - 7152. [Abstract] [Full Text] [PDF] L. B. Baughn, M. Di Liberto, R. Niesvizky, H. J. Cho, D. Jayabalan, J. Lane, F. Liu, and S. Chen-Kiang CDK2 Phosphorylation of Smad2 Disrupts TGF-{beta} Transcriptional Regulation in Resistant Primary Bone Marrow Myeloma Cells J. Immunol., February 15, 2009; 182(4): 1810 - 1817. [Abstract] [Full Text] [PDF] J. A. Lust, M. Q. Lacy, S. R. Zeldenrust, A. Dispenzieri, M. A. Gertz, T. E. Witzig, S. Kumar, S. R. Hayman, S. J. Russell, F. K. Buadi, et al. Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1{beta}-Induced Interleukin 6 Production and the Myeloma Proliferative Component Mayo Clin. Proc., February 1, 2009; 84(2): 114 - 122. [Abstract] [Full Text] [PDF] H. Niu, D. T. M. Leung, C. H. Ma, E. C. Y. Law, F. C. H. Tam, and P.-L. Lim Cells That Produce Deleterious Autoreactive Antibodies Are Vulnerable to Suicide J. Immunol., August 1, 2008; 181(3): 2246 - 2257. [Abstract] [Full Text] [PDF] T. Khong, J. Sharkey, and A. Spencer The effect of azacitidine on interleukin-6 signaling and nuclear factor-{kappa}B activation and its in vitro and in vivo activity against multiple myeloma Haematologica, June 1, 2008; 93(6): 860 - 869. [Abstract] [Full Text] [PDF] R. Piva, B. Ruggeri, M. Williams, G. Costa, I. Tamagno, D. Ferrero, V. Giai, M. Coscia, S. Peola, M. Massaia, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib Blood, March 1, 2008; 111(5): 2765 - 2775. [Abstract] [Full Text] [PDF] M. Ostad, M. Andersson, A. Gruber, and A. Sundblad Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma Blood, March 1, 2008; 111(5): 2725 - 2732. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF] L. H. Wang, X. Y. Yang, X. Zhang, and W. L. Farrar Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR{gamma} cross talk with NF-{kappa}B and C/EBP Blood, December 15, 2007; 110(13): 4373 - 4384. [Abstract] [Full Text] [PDF] B. M. Birmann, E. Giovannucci, B. Rosner, K. C. Anderson, and G. A. Colditz Body Mass Index, Physical Activity, and Risk of Multiple Myeloma Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1474 - 1478. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF] L. Pedranzini, T. Dechow, M. Berishaj, R. Comenzo, P. Zhou, J. Azare, W. Bornmann, and J. Bromberg Pyridone 6, A Pan-Janus-Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells Cancer Res., October 1, 2006; 66(19): 9714 - 9721. [Abstract] [Full Text] [PDF] T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood, May 15, 2006; 107(10): 4053 - 4062. [Abstract] [Full Text] [PDF] C. Tabata, H. Kubo, R. Tabata, M. Wada, K. Sakuma, M. Ichikawa, S. Fujita, T. Mio, and M. Mishima All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L597 - L606. [Abstract] [Full Text] [PDF] J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature Blood, August 1, 2005; 106(3): 1021 - 1030. [Abstract] [Full Text] [PDF] N. Robillard, C. Pellat-Deceunynck, and R. Bataille Phenotypic characterization of the human myeloma cell growth fraction Blood, June 15, 2005; 105(12): 4845 - 4848. [Abstract] [Full Text] [PDF] P. Tassone, P. Neri, R. Burger, R. Savino, M. Shammas, L. Catley, K. Podar, D. Chauhan, S. Masciari, A. Gozzini, et al. Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma Clin. Cancer Res., June 1, 2005; 11(11): 4251 - 4258. [Abstract] [Full Text] [PDF] F.-J. Li, N. Tsuyama, H. Ishikawa, M. Obata, S. Abroun, S. Liu, K.-i. Otsuyama, X. Zheng, Z. Ma, Y. Maki, et al. A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma Blood, April 15, 2005; 105(8): 3295 - 3302. [Abstract] [Full Text] [PDF] Z. Ma, K.-i. Otsuyama, S. Liu, S. Abroun, H. Ishikawa, N. Tsuyama, M. Obata, F.-J. Li, X. Zheng, Y. Maki, et al. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells Blood, April 15, 2005; 105(8): 3312 - 3318. [Abstract] [Full Text] [PDF] D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson Proteasome inhibitor therapy in multiple myeloma Mol. Cancer Ther., April 1, 2005; 4(4): 686 - 692. [Abstract] [Full Text] [PDF] S. Liu, H. Ishikawa, F.-J. Li, Z. Ma, K.-i. Otsuyama, H. Asaoku, S. Abroun, X. Zheng, N. Tsuyama, M. Obata, et al. Dehydroepiandrosterone Can Inhibit the Proliferation of Myeloma Cells and the Interleukin-6 Production of Bone Marrow Mononuclear Cells from Patients with Myeloma Cancer Res., March 15, 2005; 65(6): 2269 - 2276. [Abstract] [Full Text] [PDF] S. Le Gouill, K. Podar, M. Amiot, T. Hideshima, D. Chauhan, K. Ishitsuka, S. Kumar, N. Raje, P. G. Richardson, J.-L. Harousseau, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis Blood, November 1, 2004; 104(9): 2886 - 2892. [Abstract] [Full Text] [PDF] G. Descamps, C. Pellat-Deceunynck, Y. Szpak, R. Bataille, N. Robillard, and M. Amiot The Magnitude of Akt/Phosphatidylinositol 3'-Kinase Proliferating Signaling Is Related to CD45 Expression in Human Myeloma Cells J. Immunol., October 15, 2004; 173(8): 4953 - 4959. [Abstract] [Full Text] [PDF] T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF] K. Podar, G. Mostoslavsky, M. Sattler, Y.-T. Tai, T. Hayashi, L. P. Catley, T. Hideshima, R. C. Mulligan, D. Chauhan, and K. C. Anderson Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells J. Biol. Chem., May 14, 2004; 279(20): 21658 - 21665. [Abstract] [Full Text] [PDF] J. Moreaux, E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J.-F. Rossi, B. Klein, and K. Tarte BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone Blood, April 15, 2004; 103(8): 3148 - 3157. [Abstract] [Full Text] [PDF] S. Abroun, H. Ishikawa, N. Tsuyama, S. Liu, F.-J. Li, K.-i. Otsuyama, X. Zheng, M. Obata, and M. M. Kawano Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor {alpha} Blood, March 15, 2004; 103(6): 2291 - 2298. [Abstract] [Full Text] [PDF] N. Blaszczyk, B. A. Masri, N. R. Mawji, T. Ueda, G. McAlinden, C. P. Duncan, N. Bruchovsky, H.-U. Schweikert, D. Schnabel, E. C. Jones, et al. Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells Clin. Cancer Res., March 1, 2004; 10(5): 1860 - 1869. [Abstract] [Full Text] [PDF] K. Mahtouk, M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, and B. Klein An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis Blood, March 1, 2004; 103(5): 1829 - 1837. [Abstract] [Full Text] [PDF] M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence Clin. Cancer Res., October 15, 2003; 9(13): 4653 - 4665. [Abstract] [Full Text] [PDF] L. C. Platanias Map kinase signaling pathways and hematologic malignancies Blood, June 15, 2003; 101(12): 4667 - 4679. [Abstract] [Full Text] [PDF] K. Asosingh, H. De Raeve, I. Van Riet, B. Van Camp, and K. Vanderkerken Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis Blood, April 15, 2003; 101(8): 3136 - 3141. [Abstract] [Full Text] [PDF] I. Gojo, B. Zhang, and R. G. Fenton The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1 Clin. Cancer Res., November 1, 2002; 8(11): 3527 - 3538. [Abstract] [Full Text] [PDF] B. Lin, K. Podar, D. Gupta, Y.-T. Tai, S. Li, E. Weller, T. Hideshima, S. Lentzsch, F. Davies, C. Li, et al. The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment Cancer Res., September 1, 2002; 62(17): 5019 - 5026. [Abstract] [Full Text] [PDF] M. Akiyama, T. Hideshima, T. Hayashi, Y.-T. Tai, C. S. Mitsiades, N. Mitsiades, D. Chauhan, P. Richardson, N. C. Munshi, and K. C. Anderson Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line Cancer Res., July 1, 2002; 62(13): 3876 - 3882. [Abstract] [Full Text] [PDF] M. Ratta, F. Fagnoni, A. Curti, R. Vescovini, P. Sansoni, B. Oliviero, M. Fogli, E. Ferri, G. R. Della Cuna, S. Tura, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6 Blood, June 17, 2002; 100(1): 230 - 237. [Abstract] [Full Text] [PDF] A.-T. Brenne, T. Baade Ro, A. Waage, A. Sundan, M. Borset, and H. Hjorth-Hansen Interleukin-21 is a growth and survival factor for human myeloma cells Blood, May 15, 2002; 99(10): 3756 - 3762. [Abstract] [Full Text] [PDF] B. Zhang, I. Gojo, and R. G. Fenton Myeloid cell factor-1 is a critical survival factor for multiple myeloma Blood, March 15, 2002; 99(6): 1885 - 1893. [Abstract] [Full Text] [PDF] T. Ueda, N. Bruchovsky, and M. D. Sadar Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways J. Biol. Chem., February 22, 2002; 277(9): 7076 - 7085. [Abstract] [Full Text] [PDF] J. De Vos, G. Couderc, K. Tarte, M. Jourdan, G. Requirand, M.-C. Delteil, J.-F. Rossi, N. Mechti, and B. Klein Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays Blood, August 1, 2001; 98(3): 771 - 780. [Abstract] [Full Text] [PDF] V. S. Shapiro, M. N. Mollenauer, and A. Weiss Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression Blood, July 1, 2001; 98(1): 187 - 193. [Abstract] [Full Text] [PDF] M. A. Frassanito, A. Cusmai, G. Iodice, and F. Dammacco Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis Blood, January 15, 2001; 97(2): 483 - 489. [Abstract] [Full Text] [PDF] Y. Tu, A. Gardner, and A. Lichtenstein The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses Cancer Res., December 1, 2000; 60(23): 6763 - 6770. [Abstract] [Full Text] A. C. Rawstron, J. A. L. Fenton, J. Ashcroft, A. English, R. A. Jones, S. J. Richards, G. Pratt, R. Owen, F. E. Davies, J. A. Child, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells Blood, December 1, 2000; 96(12): 3880 - 3886. [Abstract] [Full Text] [PDF] M. Rowley, P. Liu, and B. Van Ness Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan Blood, November 1, 2000; 96(9): 3175 - 3180. [Abstract] [Full Text] [PDF] C. Kawamura, M. Kizaki, K. Yamato, H. Uchida, Y. Fukuchi, Y. Hattori, T. Koseki, T. Nishihara, and Y. Ikeda Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3 Blood, September 15, 2000; 96(6): 2005 - 2011. [Abstract] [Full Text] [PDF] K. Asosingh, U. Gunthert, M. H. C. Bakkus, H. De Raeve, E. Goes, I. Van Riet, B. Van Camp, and K. Vanderkerken In Vivo Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells Cancer Res., June 1, 2000; 60(11): 3096 - 3104. [Abstract] [Full Text] [PDF] B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood, April 15, 2000; 95(8): 2630 - 2636. [Abstract] [Full Text] [PDF] T. Hideshima, D. Chauhan, G. Teoh, N. Raje, S. P. Treon, Y.-T. Tai, Y. Shima, and K. C. Anderson Characterization of Signaling Cascades Triggered by Human Interleukin-6 versus Kaposi's Sarcoma-associated Herpes Virus-encoded Viral Interleukin 6 Clin. Cancer Res., March 1, 2000; 6(3): 1180 - 1189. [Abstract] [Full Text] I. Tinhofer, I. Marschitz, T. Henn, A. Egle, and R. Greil Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma Blood, January 15, 2000; 95(2): 610 - 618. [Abstract] [Full Text] [PDF] S. Barille, R. Bataille, M.-J. Rapp, J.-L. Harousseau, and M. Amiot Production of Metalloproteinase-7 (Matrilysin) by Human Myeloma Cells and Its Potential Involvement in Metalloproteinase-2 Activation J. Immunol., November 15, 1999; 163(10): 5723 - 5728. [Abstract] [Full Text] [PDF] W. Thabard, S. Barille, M. Collette, J.-L. Harousseau, M.-J. Rapp, R. Bataille, and M. Amiot Myeloma Cells Release Soluble Interleukin-6R{{alpha}} in Relation to Disease Progression by Two Distinct Mechanisms: Alternative Splicing and Proteolytic Cleavage Clin. Cancer Res., October 1, 1999; 5(10): 2693 - 2697. [Abstract] [Full Text] [PDF] S. L. Dallas, I. R. Garrett, B. O. Oyajobi, M. R. Dallas, B. F. Boyce, F. Bauss, J. Radl, and G. R. Mundy Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease Blood, March 1, 1999; 93(5): 1697 - 1706. [Abstract] [Full Text] [PDF] W. T. Bellamy, L. Richter, Y. Frutiger, and T. M. Grogan Expression of Vascular Endothelial Growth Factor and Its Receptors in Hematopoietic Malignancies Cancer Res., February 1, 1999; 59(3): 728 - 733. [Abstract] [Full Text] [PDF] K. Vanderkerken, K. Asosingh, F. Braet, I. Van Riet, and B. Van Camp Insulin-Like Growth Factor-1 Acts as a Chemoattractant Factor for 5T2 Multiple Myeloma Cells Blood, January 1, 1999; 93(1): 235 - 241. [Abstract] [Full Text] [PDF] H. Spets, P. Georgii-Hemming, J. Siljason, K. Nilsson, and H. Jernberg-Wiklund Fas/APO-1 (CD95)-Mediated Apoptosis Is Activated by Interferon-gamma and Interferon-alpha in Interleukin-6 (IL-6)-Dependent and IL-6-Independent Multiple Myeloma Cell Lines Blood, October 15, 1998; 92(8): 2914 - 2923. [Abstract] [Full Text] [PDF] M. Bihl, M. Tamm, M. Nauck, H. Wieland, A. P. Perruchoud, and M. Roth Proliferation of Human Non-Small-Cell Lung Cancer Cell Lines: Role of Interleukin-6 Am. J. Respir. Cell Mol. Biol., October 1, 1998; 19(4): 606 - 612. [Abstract] [Full Text] D. Cheleuitte, S. Mizuno, and J. Glowacki In Vitro Secretion of Cytokines by Human Bone Marrow: Effects of Age and Estrogen Status J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2043 - 2051. [Abstract] [Full Text] M. Hallek, P. Leif Bergsagel, and K. C. Anderson Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process Blood, January 1, 1998; 91(1): 3 - 21. [Full Text] [PDF] J. W. Said, M. R. Rettig, K. Heppner, R. A. Vescio, G. Schiller, H. J. Ma, D. Belson, A. Savage, I. P. Shintaku, H. P. Koeffler, et al. Localization of Kaposi's Sarcoma-Associated Herpesvirus in Bone Marrow Biopsy Samples From Patients With Multiple Myeloma Blood, December 1, 1997; 90(11): 4278 - 4282. [Abstract] [Full Text] [PDF] T. Tsunenari, Y. Koishihara, A. Nakamura, M. Moriya, H. Ohkawa, H. Goto, C. Shimazaki, M. Nakagawa, Y. Ohsugi, T. Kishimoto, et al. New Xenograft Model of Multiple Myeloma and Efficacy of a Humanized Antibody Against Human Interleukin-6 Receptor Blood, September 15, 1997; 90(6): 2437 - 2444. [Abstract] [Full Text] [PDF] S. Barille, C. Akhoundi, M. Collette, M.-P. Mellerin, M.-J. Rapp, J.-L. Harousseau, R. Bataille, and M. Amiot Metalloproteinases in Multiple Myeloma: Production of Matrix Metalloproteinase-9 (MMP-9), Activation of proMMP-2, and Induction of MMP-1 by Myeloma Cells Blood, August 15, 1997; 90(4): 1649 - 1655. [Abstract] [Full Text] [PDF] R. Bataille and J.-L. Harousseau Multiple Myeloma N. Engl. J. Med., June 5, 1997; 336(23): 1657 - 1664. [Full Text] [PDF] D. Chauhan, S. Kharbanda, A. Ogata, M. Urashima, G. Teoh, M. Robertson, D. W. Kufe, and K. C. Anderson Interleukin-6 Inhibits Fas-Induced Apoptosis and Stress-Activated Protein Kinase Activation in Multiple Myeloma Cells Blood, January 1, 1997; 89(1): 227 - 234. [Abstract] [Full Text] [PDF] M. Fourcin, S. Chevalier, C. Guillet, O. Robledo, J. Froger, A. Pouplard-Barthelaix, and H. Gascan gp130 Transducing Receptor Cross-linking Is Sufficient to Induce Interleukin-6 Type Responses J. Biol. Chem., May 17, 1996; 271(20): 11756 - 11760. [Abstract] [Full Text] [PDF] J. T. Beck, S.-M. Hsu, J. Wijdenes, R. Bataille, B. Klein, D. Vesole, K. Hayden, S. Jagannath, and B. Barlogie Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody N. Engl. J. Med., March 3, 1994; 330(9): 602 - 605. [Full Text] C. E. Dunbar and A. W. Nienhuis Multiple Myeloma: New Approaches to Therapy JAMA, May 12, 1993; 269(18): 2412 - 2416. [Abstract] [PDF] A. O. Williams, P. M. Banks, A. G. Liebelt, H. L. Stewart, and U. Saffiotti Angiofollicular Lymphoid Hyperplasia (Castleman's Disease) in Two Mice Treated with Polyoma Virus or Urethane Toxicol Pathol, January 1, 1993; 21(1): 26 - 34. [Abstract] [PDF] B. Barlogie, R. Alexanian, and S. Jagannath Plasma Cell Dyscrasias JAMA, November 25, 1992; 268(20): 2946 - 2951. [Abstract] [PDF] T Kishimoto, S Akira, and T Taga Interleukin-6 and its receptor: a paradigm for cytokines Science, October 23, 1992; 258(5082): 593 - 597. [Abstract] [PDF]

	Copyright © 1989 by American Society of Hematology         Online ISSN: 1528-0020